Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
44. Heym B, Alzari PM, Honoré N, Cole ST. Misssense mutations in the catalaseperoxidase<br />
gene, katG, are associated with isoniazid resistance in Mycobacterium<br />
tuberculosis. Mol Microbiol 1995; 15: 235-45.<br />
45. Somoskövi A, Parsons LM, Salfinger M. The molecular basis of resistance to<br />
isoniazid, rifampin, <strong>and</strong> pyrazinamide in Mycobacterium tuberculosis.<br />
2001; 2: 164-8.<br />
Respir Res<br />
46. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis.<br />
In: Hatfull GF, Jacobs WR, Jr., Eds. Molecular genetics of mycobacteria.<br />
Washington, DC: ASM Press, 2000; 235-254.<br />
47. Slayden RA, Barry CE, III. The genetics <strong>and</strong> biochemistry of isoniazid resistance<br />
in Mycobacterium tuberculosis. Microbes Infection 2000; 2: 659-69.<br />
48. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collis<br />
D, de Lisle G, Jacobs WR, Jr. inhA, a gene encoding a target <strong>for</strong> isoniazid <strong>and</strong><br />
ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-30.<br />
49. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden<br />
JDA. Characterization of the catalase-peroxidase gene (katG) <strong>and</strong> inhA locus in<br />
isoniazid-resistant <strong>and</strong> -susceptible strains of Mycobacterium tuberculosis by automated<br />
DNA sequencing: restricted array of mutations associated with drug resistance.<br />
J Infect Dis 1996; 173: 196-202.<br />
50. Parsons LM, Driscoll JR, Taber HW, Salfinger M. Drug resistance in tuberculosis.<br />
Infect Dis Clin N Am 1997; 11: 905-28.<br />
51. Heym B, Stavropoulos E, Honoré N, Domenech P, Saint-Joanis B, Wilson TM,<br />
Collins DM, Colston MJ, Cole ST. Effects of overexpression of the alkyl hydroperoxide<br />
reductase ahpC on the virulence <strong>and</strong> isoniazid resistance of Mycobacterium<br />
tuberculosis. Infect Immun 1997; 65: 1395-401.<br />
52. Canetti G, Grosset J. Teneur de souches sauvages de Mycobacterium tuberculosis<br />
en variants résistants à l’isoniazide et en variants résistants à la streptomycine<br />
sur milieu de Loewenstein-Jensen. Ann Inst Pasteur 1961; 101: 28-46.<br />
53. David HL. Probability distribution of drug-resistant mutants in unselected populations<br />
of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-4.<br />
54. Mitchison DA. Drug resistance in mycobacteria. Br Med Bull 1984; 40: 84-90.<br />
55. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid<br />
under fasting conditions, with food, <strong>and</strong> with antacids.<br />
1999; 3: 703-10.<br />
Int J Tuberc Lung Dis<br />
56. Davidson PT, Hanh LQ. Antituberculosis drugs. Clin Chest Med 1986; 7: 425-38.<br />
57. Kergueris MF, Bourin M, Larousse C. Pharmacokinetics of isoniazid: influence<br />
of age. Eur J Clin Pharmacol 1986; 30: 335-40.<br />
58. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin<br />
Pharmacokinetics 1979; 4: 401-22.<br />
174
Change language